Regional localization of [14C]mescaline in rabbit brain after intraventricular administration
Nandkumar S. Shah, O. D. Dulati, D. A. Powell, Vicki Kleinburd
Neurochemical Research June 1, 1977 DOI: 10.1007/bf00969357 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental animal study Peer reviewed |
|---|---|
| Population | Albino rabbits of either sex |
| Interventions | mescaline chlorpromazine iproniazid |
| Dose | 0.5 μmol mescaline in 0.05 ml saline; chlorpromazine 15 mg/kg i.p.; iproniazid 150 mg/kg i.p. |
| Duration | 180 minutes after injection |
| Topics | Mescaline |
| Keywords | Cerebrum Medulla oblongata Pons Inferior colliculus Midbrain Hippocampus Tegmentum Cerebellum Endocrinology Central nervous system |
| Citations | 2 |
| Key findings | Intraventricular mescaline rapidly distributes across rabbit brain regions, with highest concentrations in spinal cord and colliculi; chlorpromazine reduces mescaline in limbic areas while iproniazid uniformly lowers its metabolite TMPA. |
Abstract
Albino rabbits of either sex were anesthetized, and a cannula was implanted permanently into the lateral ventricle. About 1 week later, the distribution of [(14)C]mescaline and its deaminated metabolite, [(14)C]trimethoxyphenylacetic acid ([(14)C]TMPA) in 12 brain regions was examined at 15, 60, and 180 min after the intraventricular injection of [(14)C]mescaline (0.5 μmol in 0.05 ml saline).(14)C-radioactivity was rapidly distributed in all regions, reaching peak levels within 15 min. The spinal cord, superior colliculus, pons, hypothalamus, caudate, medulla oblongata, and inferior colliculus contained 23-57 nmol/g of mescaline; the thalamus, tegmentum, and cerebellum, 12-15 nmol/g; and the cerebrum and hippocampus, less than 10 nmol/g; the levels of [(14)C]TMPA ranged from 0.5 to 5 nmol/g. The levels of [(14)C]mescaline and of [(14)]TMPA in all brain areas were considerably decreased 180 min after its injection. Pretreatment with chlorpromazine (15 mg/kg, i.p., 30 min) lowered [(14)C]mescaline concentrations in the hippocampus, caudate, thalamus, and cerebrum and elevated them in the spinal cord, medulla oblongata, pons, and tegmentum; [(14)C]TMPA levels as the percentage of total radioactivity were not affected. Pretreatment with iproniazid (150 mg/kg, i.p., 18 h), on the other hand, uniformly reduced the TMPA levels in all brain areas, with the resultant increases in mescaline levels. The CPZ-effect in lowering the mescaline concentrations in the areas belonging to the limbic system may have significance in explaining its antihallucinogenic effect in humans and its ability to block the altered behavior induced by the latter drug in laboratory animals.
Comparable studies
Other preclinical and animal studies on mescaline, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. C57BL/6J mice | 2020 | Experimental study with dose-response experiments | |
| Brain mechanisms of hallucinogens and entactogens Humans and rats | 2001 | Review | |
| Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology Zebrafish (Danio rerio) | 2012 | Experimental study | |
| Lysergic Acid Diethylamide- and Mescaline-Induced Attenuation of the Effect of Punishment in the Rat Rats | 1976 | Experimental study | |
| Dihydrobenzofuran Analogues of Hallucinogens. 3. Models of 4-Substituted (2,5-Dimethoxyphenyl)alkylamine Derivatives with Rigidified Methoxy Groups Rats (trained to discriminate saline from LSD tartrate) and rat cortical and... | 1996 | In vivo drug discrimination assay and in vitro radioligand binding assay |